
Phase 2 Trial: Cytokinetics Launches AMBER-HFpEF Study of CK-586 in Symptomatic HFpEF
Introduction: Cytokinetics Advances CK-586 into Phase 2 Trial Cytokinetics, Incorporated a leading biopharmaceutical company, has announced that enrollment is now open for AMBER-HFpEF, a pivotal Phase 2 clinical trial evaluating…












